[Lipid metabolism alterations produced by hepatitis C virus in patients with chronic infection.]

Ainara Muñoz-Cabrejas1, Silvia Espina Cadena2, José Miguel Arbonés-Mainar3

  • 1Adipocyte and Fat Biology Laboratory (AdipoFat). Unidad de Investigación Traslacional. Hospital Universitario Miguel Servet. Instituto Aragonés de Ciencias de la Salud (IACS). Instituto de Investigación Sanitaria de Aragón (IIS Aragón). Zaragoza. España.

Insights

Chronic hepatitis C virus (HCV) infection lowers lipid levels but paradoxically increases cardiovascular disease risk. Further research is needed on direct-acting antivirals and their impact on lipid metabolism and heart health.

Area of Science:

  • Hepatology
  • Cardiology
  • Lipid Metabolism

Background:

  • Chronic hepatitis C virus (HCV) infection is associated with an altered lipid profile.
  • Despite a seemingly favorable lipid profile, HCV patients exhibit increased cardiovascular events.
  • The relationship between HCV-induced metabolic changes and cardiovascular disease risk requires clarification.

Purpose of the Study:

  • To review and synthesize studies on HCV's impact on lipid metabolism.
  • To investigate the association between HCV infection, lipid changes, and cardiovascular disease.

Main Methods:

  • Bibliographic search of Medline and Scopus databases (January 2008 - February 2019).
  • Inclusion and exclusion criteria applied to 901 identified publications.
  • Review of 10 selected studies.

Main Results:

  • Chronic HCV infection decreased total cholesterol and lipid fractions.
  • No significant association found with triglyceride levels.
  • Evidence suggests HCV infection increases atherosclerosis and cardiovascular disease risk.

Conclusions:

  • Chronic HCV infection exerts a lipid-lowering effect and elevates cardiovascular risk.
  • Prospective studies are necessary to evaluate direct-acting antivirals' effects on lipid metabolism and cardiovascular risk.
Abstract

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
155
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
120
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
143
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
4.5K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
130